Ocular myasthenia Trials in Disease

Study on the Effectiveness and Safety of Efgartigimod in Adults with Ocular Myasthenia Gravis

This trial is investigating Efgartigimod, also known by its code name ARGX-113, as a potential treatment for adults with ocular myasthenia gravis. The medication is administered as a subcutaneous injection, meaning it is given under the skin using a pre-filled syringe. The trial compares Efgartigimod with a placebo to determine how well it works and whether it is safe for treating this condition.

Main inclusion criteria:

• Participants must be at least 18 years old and meet the legal age of consent for clinical studies in their area
• Must have a confirmed diagnosis of myasthenia gravis supported by a positive test for AChR-Ab (a specific antibody) or abnormal results in nerve and muscle function tests
• Should have a history of improvement with standard myasthenia gravis treatment
• Must be classified as MGFA Class I, which indicates weakness in the muscles around the eyes
• Must have a score of at least 6 on the MGII ocular score, with at least 2 eye-related items scoring at least 2

Main exclusion criteria:

• People with any other serious health condition that could interfere with the study
• Individuals with recent infections or illnesses that could affect study results
• Those currently taking medications that might interfere with the study treatment
• People with a history of allergic reactions to similar treatments
• Pregnant or breastfeeding individuals
• Recent participation in another clinical trial
• History of drug or alcohol abuse
• Recent surgery or planned surgery during the study period
• History of certain eye conditions that could affect the study
• Inability to comply with study procedures or follow-up visits

Focus and goals: The study aims to assess how well Efgartigimod works in improving symptoms of this condition and to ensure it is safe for use. Efgartigimod works by modulating the immune system to reduce levels of antibodies that attack the body's own tissues, thereby helping to alleviate symptoms. Throughout the study, participants will be monitored for changes in their eye muscle symptoms and overall well-being. The trial uses specific scoring systems to measure improvements in muscle strength around the eyes, particularly the MGII ocular score and MG-ADL ocular domain scores. Safety evaluations include regular checks for any adverse effects, routine laboratory tests, vital sign monitoring, and ECG assessments. The study is expected to conclude by April 2028.

Investigational drug: Efgartigimod PH20 SC is administered using a prefilled syringe and is classified as an immunomodulatory agent. This Phase 3 clinical trial is evaluating its effectiveness and safety specifically for treating the eye muscle weakness associated with this condition.